You just read:

AbbVie's HUMIRA® (adalimumab) receives Health Canada approval for the extension of the Polyarticular Juvenile Idiopathic Arthritis indication for patients between 2 and 4 years

News provided by

AbbVie

Dec 09, 2015, 09:00 ET